Additionally, upregulation of the IL-6/STAT3 pathway has been detected in ER + breast cancer resistant to CDK4/6i palbociclib, which mediates the upregulation of EMT and BCSCs pathways. This evidence concerns the gene STAT3 and breast carcinoma.